Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di terapie mirate per il trattamento dei partecipanti adulti con artrite psoriasica attiva

5 novembre 2026 aggiornato da: AbbVie

Un studio multicentrico di fase 2, randomizzato, piattaforma di terapie mirate per il trattamento di soggetti adulti con artrite psoriasica attiva

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.

The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

300

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Quebec
      • Sherbrooke, Quebec, Canada, J1G 2E8
        • Reclutamento
        • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
      • Trois-Rivières, Quebec, Canada, G9A 3X2
        • Reclutamento
        • Centre de Recherche Musculo-Squelettique /ID# 274397
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7H 0P4
        • Reclutamento
        • Dr. Latha Naik Medical Professional Corporation /ID# 272803
      • Uherské Hradiště, Cechia, 686 01
        • Reclutamento
        • Medical Plus Research /ID# 272363
      • Zlín, Cechia, 760 01
        • Reclutamento
        • PV Medical Services /ID# 272368
    • Brno-mesto
      • Brno, Brno-mesto, Cechia, 638 00
        • Reclutamento
        • Revmatologie /ID# 272367
    • Moravian-Silesian Region
      • Hlučín, Moravian-Silesian Region, Cechia, 748 01
        • Reclutamento
        • L.K.N. Arthrocentrum /ID# 272366
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, Francia, 06001
        • Reclutamento
        • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
    • Auvergne-Rhône-Alpes
      • Caluire-et-Cuire, Auvergne-Rhône-Alpes, Francia, 69300
        • Reclutamento
        • Infirmerie Protestante De Lyon /ID# 273731
    • Indre-et-Loire
      • Chambray-lès-Tours, Indre-et-Loire, Francia, 37170
        • Reclutamento
        • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
    • Loiret
      • Orléans, Loiret, Francia, 45067
        • Completato
        • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
    • New Aquitaine
      • Bordeaux, New Aquitaine, Francia, 33076
        • Completato
        • Chu Bordeaux - Hopital Pellegrin /ID# 273390
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polonia, 85-068
        • Reclutamento
        • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
    • Masovian Voivodeship
      • Pruszków, Masovian Voivodeship, Polonia, 05-800
        • Reclutamento
        • MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
      • Warsaw, Masovian Voivodeship, Polonia, 02-665
        • Reclutamento
        • Centrum Medyczne Reuma Park /ID# 273301
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polonia, 15-351
        • Completato
        • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
    • Warmian-Masurian Voivodeship
      • Elblag, Warmian-Masurian Voivodeship, Polonia, 82-300
        • Completato
        • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
    • California
      • Huntington Beach, California, Stati Uniti, 92648-5994
        • Reclutamento
        • Newport Huntington Medical Group /ID# 272764
        • Contatto:
          • Site Coordinator
          • Numero di telefono: 714-923-7112
    • Florida
      • Avon Park, Florida, Stati Uniti, 33825
        • Reclutamento
        • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
        • Contatto:
          • Site Coordinator
          • Numero di telefono: 863-314-8555
      • Clearwater, Florida, Stati Uniti, 33765
        • Reclutamento
        • Clinical Research Of West Florida - Phase I Unit /ID# 273198
      • Orlando, Florida, Stati Uniti, 32819
        • Reclutamento
        • HMD Research LLC /ID# 273086
      • Tamarac, Florida, Stati Uniti, 33321
        • Reclutamento
        • West Broward Rheumatology Associates /ID# 272892
      • Tampa, Florida, Stati Uniti, 33606
        • Reclutamento
        • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
        • Contatto:
          • Site Coordinator
          • Numero di telefono: (813) 870-1292
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
      • Skokie, Illinois, Stati Uniti, 60076
        • Completato
        • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
      • Willowbrook, Illinois, Stati Uniti, 60527
        • Reclutamento
        • Willow Rheumatology and Wellness /ID# 277354
    • Maryland
      • Cumberland, Maryland, Stati Uniti, 21502
        • Completato
        • Klein & Associates /ID# 272829
    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03756
        • Reclutamento
        • Dartmouth-Hitchcock Medical Center /ID# 272702
        • Contatto:
          • Site Coordinator
          • Numero di telefono: 603-650-4717
    • Ohio
      • Middleburg Heights, Ohio, Stati Uniti, 44130
        • Reclutamento
        • Paramount Medical Research and Consulting /ID# 272757
    • Pennsylvania
      • Duncansville, Pennsylvania, Stati Uniti, 16635
        • Reclutamento
        • Altoona Center For Clinical Research /ID# 272593
        • Contatto:
          • Site Coordinator
          • Numero di telefono: 814-296-6108
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38119
        • Reclutamento
        • Private Practice - Dr. Ramesh C. Gupta /ID# 272897
    • Texas
      • Austin, Texas, Stati Uniti, 78745
        • Reclutamento
        • Tekton Research - West Gate /ID# 272765
      • Frisco, Texas, Stati Uniti, 75035
        • Reclutamento
        • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
      • Houston, Texas, Stati Uniti, 77089-6142
        • Reclutamento
        • Accurate Clinical Research - Houston /ID# 272754
      • San Antonio, Texas, Stati Uniti, 78251
        • Reclutamento
        • Tekton Research, LLC /ID# 272901
      • Tomball, Texas, Stati Uniti, 77375
        • Reclutamento
        • DM Clinical Research - Tomball /ID# 272760
      • Budapest, Ungheria, 1027
        • Reclutamento
        • Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
      • Budapest, Ungheria, 1023
        • Reclutamento
        • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
    • Borsod-Abauj Zemplen county
      • Miskolc, Borsod-Abauj Zemplen county, Ungheria, 3529
        • Reclutamento
        • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
    • Fejér
      • Székesfehérvár, Fejér, Ungheria, 8000
        • Reclutamento
        • Complex Rendelo Med Zrt. /ID# 272570
      • Veszprém, Fejér, Ungheria, 8200
        • Reclutamento
        • Vital-Medicina /ID# 272855

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
  • Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
  • Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
  • Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
  • Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria:

  • Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
  • Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
  • Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Substudy 1: Risankizumab Monotherapy

Participants will receive risankizumab

Subcutaneous (SC) Injection

Sperimentale: Substudy 1: Lutikizumab Monotherapy

Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week.

Subcutaneous (SC) Injection

Sperimentale: Substudy 1: Lutikizumab and Risankizumab Combination Therapy

Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

Sperimentale: Substudy 2: ABBV-701 Monotherapy

Participants will initially receive ABBV-701.

Subcutaneous (SC) Injection

Sperimentale: Substudy 2: Risankizumab Monotherapy

Participants will receive risankizumab.

Subcutaneous (SC) Injection

Sperimentale: Substudy 2: ABBV-701 and Risankizumab Combination Therapy

Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

Sperimentale: Substudy 3: ABBV-547 Dose A

Participants will receive ABBV-547 Dose A.

Subcutaneous (SC) Injection

Sperimentale: Substudy 3: ABBV-547 Dose B

Participants will receive ABBV-547 Dose B.

Subcutaneous (SC) Injection

Sperimentale: Substudy 3: ABBV-547 Dose C

Participants will receive ABBV-547 Dose C.

Subcutaneous (SC) Injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Lasso di tempo: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

  1. ≥ 50% improvement in 68-tender joint count;

  2. ≥ 50% improvement in 66-swollen joint count; and

  3. ≥ 50% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Number of Participants With Adverse Events (AEs)
Lasso di tempo: Up to Week 52

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to Week 52

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
Lasso di tempo: At Week 16

A participant was classified as achieving MDA if 5 of the following 7 criteria were met:

  • Tender joint count (out of 68 joints) ≤ 1
  • Swollen joint count (out of 66 joints) ≤ 1
  • PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3%
  • Participant's assessment of pain ≤ 1.5 (NRS from 0 to 10)
  • Participant's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10)
  • HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3)
  • Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
At Week 16
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Lasso di tempo: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

  1. ≥ 20% improvement in 68-tender joint count;

  2. ≥ 20% improvement in 66-swollen joint count; and

  3. ≥ 20% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Lasso di tempo: At Week 16

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:

  1. ≥ 70% improvement in 68-tender joint count;

  2. ≥ 70% improvement in 66-swollen joint count; and

  3. ≥ 70% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
Lasso di tempo: At Week 16

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked).

The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

At Week 16

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: ABBVIE INC., AbbVie

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 aprile 2025

Completamento primario (Stimato)

1 agosto 2029

Completamento dello studio (Stimato)

1 agosto 2029

Date di iscrizione allo studio

Primo inviato

4 marzo 2025

Primo inviato che soddisfa i criteri di controllo qualità

4 marzo 2025

Primo Inserito (Effettivo)

7 marzo 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • M25-191
  • 2024-519291-11 (Substudy 1) (Altro identificatore: EU CT)
  • 2026-525937-21 (Substudy 2) (Altro identificatore: EU CT)
  • 2026-527719-41 (Substudy 3) (Altro identificatore: EU CT)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Periodo di condivisione IPD

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Criteri di accesso alla condivisione IPD

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi